N/A
N=13
Efficacy and Safety of ICD Remote Monitored Exercise Testing to Improve Heart Failure Outcomes: REMOTE HF-ACTION
Heart Failure
Bottom Line
View on ClinicalTrials.gov: NCT04629066 ↗Enrolled (actual)
13
Serious AEs
7.7%
Results posted
Aug 2023
Primary outcome: Primary: Abbott Implantable Cardioverter-defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) Device Measured Daily Physical Activity (PA) — 129.3; 171.4 minutes per day
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Remote Cardiac Rehabilitation (CR) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Abbott Implantable Cardioverter-defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) Device Measured Daily Physical Activity (PA) |
129.3; 171.4 | — |
| SECONDARY Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Heart Failure (HF) Symptoms Severity Score |
5.2; 11.5 | — |
| SECONDARY Number of Heart Failure Hospitalization, Fracture, Myocardial Infarction, Serious Adverse Arrhythmia, and ICD Therapy Combination Events |
1; 1 | — |
| SECONDARY Kansas City Cardiomyopathy Questionnaire (KCCQ) Heart Failure (HF) Symptom Severity Score |
86.1; 93.8 | — |
Summary
This single center randomized controlled trial will involve 50 medically stable outpatients with HF, reduced ejection fraction, and previously implanted ICD or CRT-D devices followed longitudinally on the Abbott Medical Merlin remote patient monitoring network. Patients will be randomized in a 1:1 fashion to usual care plus a remotely administered home based weekly prescription for aerobic exercise (intervention) or usual care alone (control). Usual care will include regularly scheduled visits with the clinical heart failure care team and medical therapy as prescribed by that team. The exercise prescription will be created by an exercise physiologist after incorporating remotely collected data from a patient directed smartphone app assessing HF symptom severity, vital signs, weight, and blood sugar, implantable device measures of physical activity, heart rate, heart failure volume status and heart rhythm, and Fitbit measures of physical activity.
Eligibility Criteria
Inclusion Criteria
- Patients have a MERLIN patient registry record for an ICD or CRT-D implantation between 01/01/2010-12/31/2020
- Age > 18 years
- Left ventricular ejection fraction 12 months
- To allow for a post-surgical adjustment period, patients must be >30 days out from device implantation
Exclusion Criteria
- Prior participation in CR- by patient questionnaire
- Unwillingness to sign informed consent form
- Currently performing > 240 minutes of device detected daily PA- by ICD/CRTD remotely collected data.
- Lack of a smartphone or unwillingness to use an App or Fitbit device
- Prior left ventricular assist device (LVAD) implantation or heart transplantation
- ICD tachyarrhythmia therapies programmed off
- Inherited arrhythmia condition with contraindication to exercise (eg Lamin A mutation or ARVC)
- No transmissions through Merlin.net in past 12 months
Data sourced from ClinicalTrials.gov (NCT04629066). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.